Project: Personalization of Long term Treatment in Bipolar Disorder

Acronym PLOT-BD (Reference Number: ERAPERMED2018-263)
Duration 01/03/2019 - 28/02/2022
Project Topic We propose a genomics-based approach to precision medicine for bipolar disorder. Our main objective is to develop clinically applicable methods of selecting optimal long-term treatment, with a focus on lithium. To this end we established a partnership of specialized clinical programs and expert molecular-genetic laboratories. Our proposed studies will combine novel techniques of cellular phenotyping and epigenetic mapping. We will draw on unique clinical sample that will make this proposal possible and will extend the recruitment. The project has three related aims: Aim 1: Replication of the molecular genetic predictors of lithium response in a large Caucasian cohort with a standardized assessment Aim 2: Testing the hypothesis of differential DNA methylation in responders and non-responders to lithium and integrating epigenomic and genomic information to predict treatment response Aim 3: Characterization of the cellular and molecular phenotypes of neurons (electrophysiological profiles, mitochondrial functioning and transcriptomic profiles) derived from induced pluripotent stem cells of patients with bipolar disorder responsive and non-responsive to lithium as well as of fast and slow responders. Our results will 1) guide design of replication and validation studies, and 2) contribute to developments of personalized clinical management of bipolar disorder.
Network ERA PerMed
Call 1st Joint Transnational Call for Proposals (2018)

Project partner

Number Name Role Country
1 Dalhousie University Coordinator Canada
2 McGill University Partner Canada
3 Inserm U894 Partner France
4 University Hospital Würzburg Partner Germany
5 University of Cagliari Partner Italy